Journals / Arşiv Kaynak Tarama Dergisi / 2019 / Cilt: 28 - Sayı: 4

Medication Related Osteonecrosis of Jaws and Current Treatment Modalities

Çenelerin İlaca Bağlı Osteonekrozu ve Güncel Tedavi Yaklaşımları

Pages
285–299
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, the articles published in the literature about the applied treatments the guideline in until 2018 were compiled.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Medication-related osteonecrosis of the jaws (MRONJ), resulting from maxillofacial surgical procedures applied during or after bisphosphonate, antiresorptive and antiangiogenic treatments is a recently defined disease and its etiopathogenesis is still unexplained.
📊
Key Findings & Data:It is of utmost importance to prevent the occurence of this disease in patients, who are referred to oral and maxillofacial surgeons, informed about this disease and from the most recent guideline in 2014 motivated about preventive methods.
💡
Conclusion & Impact:In this review, the articles published in the literature about the applied treatments the guideline in until 2018 were compiled.
🔬Design:Review & Systematic Survey
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Medication-related osteonecrosis of the jaws (MRONJ), resulting from maxillofacial surgical procedures applied during or after bisphosphonate, antiresorptive and antiangiogenic treatments is a recently defined disease and its etiopathogenesis is still unexplained. There are debates on the treatment approaches of the disease, and the commission established by the American Association for Maxillofacial Surgery publishes guidelines on the definition, staging and treatment procedures of the disease. Nowadays, surgical and conservative treatment methods are used depending on the impact level of bone and soft tissues. It is of utmost importance to prevent the occurence of this disease in patients, who are referred to oral and maxillofacial surgeons, informed about this disease and from the most recent guideline in 2014 motivated about preventive methods. In this review, the articles published in the literature about the applied treatments the guideline in until 2018 were compiled.

Özet

Çenelerin ilaca bağlı osteonekrozu (MRONJ); antirezorptif, antianjiyogenik ve bisfosfonat tedavileri esnasında veyasonrasında uygulanan maksillofasyal cerrahi işlemler ile ortaya çıkan; yeni tanımlanan ve halen etyopatogenezi tamanlaşılamamış bir hastalıktır. Amerikan Maksillofasyal Cerrahlar Birliği’nin oluşturduğu komisyon tarafından hastalığıntanımı, evrelendirilmesi ve tedavi yaklaşımları konusunda çalışmalar değerlendirilmekte ve bu konularda görüş bildirenkılavuzlar yayınlanmakta olup; hastalığın tedavi yaklaşımları konusunda henüz tartışmalar devam etmektedir. Kemik veyumuşak dokuların etkilenme düzeyine bağlı olarak, hastalığın tedavisinde konservatif ve cerrahi yöntemlerkullanılmaktadır. Hastalığın oluşumunun önlenmesi için ağız, diş ve çene cerrahlarına başvuran hastaların bu hastalıkhakkında bilgilendirilmesi ve koruyucu yöntemler hakkında motive edilmeleri büyük önem taşımaktadır. Bu derlemede,en son yayınlanan 2014 yılındaki kılavuz sonrasından 2018 yılına kadar literatürde bildirilen ve uygulanmış tedavilerikonu alan makaleler derlenmiştir.

🔖

Cite This Article

AKBULUT, N., SOYLU, E., ERDİL, A., ALTAN, A. (2022). Medication Related Osteonecrosis of Jaws and Current Treatment Modalities. Arşiv Kaynak Tarama Dergisi, Cilt: 28 - Sayı: 4, 285–299. https://ajindex.com/articles/449124

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7
  2. Ruggiero SL, Dodson TB. American Association of Oral and Maxillofacial Surgeons position Paper on Medication-Related Osteonecrosis of the Jaws- 2014 Update. Am Assoc Oral Maxillofac Surg. 2014;72:2381-2
  3. Fleisch HA, Russell RGG, Bisaz S, Hlbauer RCM. The Inhibitory Effect of Phosphonates on the Formation of Calcium Phosphate Crystals in vitro and on Aortic and Kidney Calcification in vivo. 1970;18:12-18
  4. Sinclair HM. the Editor. Lancet. 1958;vi:1957-1959
  5. Bartel R, Frisch B, Tresckow E Von, Bartl C. Bisphosphonates in Medical Practice. 1st ed. Heidelberg Berlin, Springer, 2007
  6. Vile R. Cancer therapy: Less blood means more sanguinity. Curr Biol. 1995;5:10-13
  7. Brunello A, Saia G, Bedogni A, Scaglione D, Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone. 2009;44:173-5
  8. Pageau SC. Denosumab. MAbs. 2009;1:210-5
  9. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-31
  10. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 2010;48:221-3
  11. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527-34
  12. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104-7
  13. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253-4
  14. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the Jaw in a Patient on Denosumab. J Oral Maxillofac Surg. 2010;68:959-63
  15. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. J Clin Oncol. 2010;28:5132-9
  16. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.